Further research into SMO/GLI-targeted combination therapies and immune checkpoint modulation in advanced BCC may help improve patient outcomes, as persistent, treatment-refractory disease with skull invasion can lead to chronic wounds that are highly susceptible to life-threatening infections such as MSSA brain abscesses, especially in immunosuppressed patients. The gene discussed is GLI1; the disease is skin basal cell carcinoma.